Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 50Observational 1

Sponsor

Cancer Type

Gastrointestinal 41Thoracic 15Breast 8Genitourinary 7Gynecologic 4Tumor-Agnostic 3CNS 3Other solid neoplasm 1Dermatologic 1

Conditions

Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

Blood Specimen Collection 22Surveys and Questionnaires 19Nivolumab 14Ipilimumab 12pembrolizumab 11Gene Expression Profiling 11Biopsy 10trametinib 9dabrafenib 8Flow Cytometry 8Specimen Handling 7Polymerase Chain Reaction 7Tomography, Optical Coherence 6Therapeutics 6Immunohistochemistry 6Imiquimod 6Amplified Fragment Length Polymorphism Analysis 6Watchful Waiting 5Psychiatric Rehabilitation 5Immunotherapy 5Data Collection 53-ingenyl angelate 5Mohs Surgery 4Microarray Analysis 4Interviews as Topic 4Immunoenzyme Techniques 4Drug Therapy 4Dermoscopy 4sonidegib 3encorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Bevacizumab × Dermatologic × Clear all
NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡